198 episodes

Join the GOLD team for a weekly exploration of all things pharma, featuring thought-provoking conversations, insightful interviews with high-profile industry guests and discussions about the latest trends and innovations taking the pharmaceutical sphere by storm.

Whether its marketing, medical affairs, the use of digital techniques to create patient-centric approaches or something in between, there's something here for anyone interested in the pharmaceutical industry.

The GOLD Podcast: Weekly Pharma Insights EMJ

    • Business
    • 5.0 • 2 Ratings

Join the GOLD team for a weekly exploration of all things pharma, featuring thought-provoking conversations, insightful interviews with high-profile industry guests and discussions about the latest trends and innovations taking the pharmaceutical sphere by storm.

Whether its marketing, medical affairs, the use of digital techniques to create patient-centric approaches or something in between, there's something here for anyone interested in the pharmaceutical industry.

    Luca Dezzani and Luisa Luciani-Silverman on medical affairs

    Luca Dezzani and Luisa Luciani-Silverman on medical affairs

    For this week’s GOLD nugget, Helena highlights not one but two of GOLD’s previous guests from the world of Medical Affairs: Luca Dezzani, Vice President, Oncology Medical Affairs, Johnson & Johnson, and Luisa Luciani-Silverman, US Medical Head of Immuno-Oncology, AstraZeneca. They explore the potential value that can come from collaborating with different industries and some tips for measuring the value of medical affairs – it’s not one to be missed!
     
    If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
    Luca’s full episode: https://www.emg-gold.com/post/podcast-medical-affairs-evolution-and-the-future-for-msls
    Luisa’s full episode: https://www.emg-gold.com/post/podcast-real-world-evidence-the-metrics-of-medical-affairs-and-tiktok-marketing
    The Leap from Medicine to Medical Affairs: https://www.emg-gold.com/post/the-leap-from-medicine-to-medical-affairs

    • 10 min
    GSK's Judy Stewart on vaccines

    GSK's Judy Stewart on vaccines

    The GOLD Podcast may be on a break, but Helena is still here to provide you with some great insights – or GOLD Nuggets, if you will – from key opinion leaders in the pharmaceutical industry. In this special episode, she looks back at the very first episode of Season 2 which featured Judy Stewart, Senior Vice President and Head of US Vaccines at GSK. Helena considers some of the gold nuggets that Judy shared, including insights on both the vaccine industry and her approach to leadership.
    If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
     
    Judy's full podcast episode: https://www.emg-gold.com/post/vaccines-leadership-and-blockchain
    Judy's Catalyst interview https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases
    GSK warns against routine vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency
    Haleon demerger completed by GSK https://www.emg-gold.com/post/haleon-demerger-completed-by-gsk

    • 6 min
    Season finale: MMR and vaccines past, present and future

    Season finale: MMR and vaccines past, present and future

    As Helena and Marc wrap up this season, they’re joined by Mike Watson, Chief Executive Officer of Mevox – a company committed to bringing vaccine technology into the 21st century.
     
    Mike discusses the importance of developing new measles, mumps and rubella (MMR) vaccines, Mevox’s success so far in achieving this ambition – reaching series B funding – and its future trajectory, how COVID-19 will impact the future of vaccine development, along with a whole host of other fascinating insights. As Helena’s favourite interview of Season 2, it’s not one to be missed!
     
    If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
    The return of the vaccines https://www.emg-gold.com/post/the-return-of-the-vaccines
    Routine vaccinations: road to recovery https://www.emg-gold.com/post/routine-vaccinations-road-to-recovery
    A heyday for mRNA https://www.emg-gold.com/post/a-heyday-for-mrna
    Moderna set to bring mRNA innovation to UK https://www.emg-gold.com/post/moderna-set-to-bring-mrna-innovation-to-uk
    GSK warns against vaccine complacency https://www.emg-gold.com/post/gsk-warns-against-routine-vaccine-complacency

    • 35 min
    S02 E22: Key pharma trends from Cannes Lions

    S02 E22: Key pharma trends from Cannes Lions

    This week, Claire Gillis, CEO, VMLY&R Health joins Helena and Marc on the airwaves to discuss the health and pharma highlights from the recent Cannes Lions International Festival, including the power of technology, how to spend smart on campaigns and her top moment from the festival this year.
    If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
    Talking to Claire Gillis https://www.emg-gold.com/post/podcast-talking-to-claire-gillis
    Innovative tech, pharma supply chains and more https://www.emg-gold.com/post/podcast-innovative-tech-pharma-supply-chains-and-more
    Spoonful of technology https://www.emg-gold.com/post/spoonful-of-technology-5
    Cardiovascular catalyst launched by Novartis https://www.emg-gold.com/post/cardiovascular-catalyst-launched-by-novartis

    • 16 min
    S02 E21: Big pharma vs biotech and the future of marketing

    S02 E21: Big pharma vs biotech and the future of marketing

    In an interview double bill, Helena and Marc are joined two fantastic guests from the worlds of pharma marketing and commercial affairs. Michele Manto, Chief Commercial Officer, Galapagos, shares his thoughts on the differences in leading a large pharma company and an agile biotech, amongst other exciting topics, while Robert Grimm, Digital Marketing and Transformation Manager, Novo Nordisk, talks all things marketing with insights into developing campaigns.
     
    If you’re interested in learning more about the topic areas discussed in this episode, check out the following content: 
     
    A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech 
    Time to turn to TikTok https://www.emg-gold.com/post/time-to-turn-to-tiktok 
    Bridging the digital health divide https://www.emg-gold.com/post/bridging-the-digital-health-divide
    The driving seat of organisational change https://www.emg-gold.com/post/the-driving-seat-of-organisational-change 

    • 35 min
    S02 E20: Meet GOLD's recent catalyst – Claus Zieler

    S02 E20: Meet GOLD's recent catalyst – Claus Zieler

    In this episode, GOLD is joined by recent catalyst interviewee Claus Zieler, President of Established Markets, Astellas, who discusses crisis management, the importance of leaders in shaping company culture, the innovation he is most excited about, and much more.
     
    If you’re interested in learning more about the topic areas discussed in this episode, check out the following content:
     
    Claus Zieler on leadership https://www.emg-gold.com/post/claus-zieler-on-leadership
     
    Reverse mentoring: a how-to guide https://www.emg-gold.com/post/reverse-mentoring-a-how-to-guide
     
    Supporting patients in a war zone https://www.emg-gold.com/post/supporting-patients-in-a-war-zone
     
    The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies

    • 23 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Business

Ramsey Network
iHeartPodcasts
NPR
Andy Frisella #100to0
Guy Raz | Wondery
BiggerPockets

You Might Also Like